Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial | Synapse
April 10, 2026Open Access
Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial
Key Points
This research aims to assess the rebound effect on myopia progression after stopping 0.01% atropine treatment for three years.
Conducted as part of the CHAMP clinical trial.
Participants received 0.01% atropine for myopia control.
Myopia progression was monitored for four years, including one year post-treatment.
Minimal rebound in myopia progression observed after stopping treatment.
Results demonstrate sustained efficacy of 0.01% atropine for myopia control over three years.
Abstract
The Childhood Atropine for Myopia Progression (CHAMP) study was registered in clinicaltrials.gov (NCT03350620, registration date November 17, 2017).